# Multi-ancestry genome-wide association meta-analysis of mosaic loss of chromosome Y in the Million Veteran Program identifies 167 novel loci

Michael Francis<sup>1,2†</sup>, Bryan R. Gorman<sup>1,2†</sup>, Tim B. Bigdeli<sup>3,4†</sup>, Giulio Genovese<sup>5,6,7†</sup>, 4 Georgios Voloudakis<sup>8,9</sup>, Jaroslav Bendl<sup>9</sup>, Biao Zeng<sup>9</sup>, Sanan Venkatesh<sup>8,9</sup>, Chris 5 Chatzinakos<sup>4</sup>, Erin McAuley<sup>1,2</sup>, Sun-Gou Ji<sup>1,33</sup>, Kyriacos Markianos<sup>1</sup>, Patrick A. 6 Schreiner<sup>1,2</sup>, Elizabeth Partan<sup>10</sup>, Yunling Shi<sup>11</sup>, Poornima Devineni<sup>11</sup>, VA Million Veteran 7 Program\*, Jennifer Moser<sup>12</sup>, Sumitra Muralidhar<sup>12</sup>, Rachel Ramoni<sup>12</sup>, Alexander G. 8 Bick<sup>13</sup>, Pradeep Natarajan<sup>5,14,15</sup>, Themistocles L. Assimes<sup>16,17</sup>, Philip S. Tsao<sup>16,17,18</sup>, 9 Derek Klarin<sup>19,20</sup>, Catherine Tcheandjieu<sup>21,22,23,24</sup>, Neal S. Peachey<sup>25,26,27</sup>, Sudha K. 10 Ivengar<sup>25,28,29,30,31</sup>. Panos Roussos<sup>8,9</sup>, Saiju Pyarajan<sup>1,32‡</sup> 11

<sup>1</sup>Center for Data and Computational Sciences (C-DACS), VA Cooperative Studies Program, VA 12 Boston Healthcare System, Boston, MA, 02130, USA, <sup>2</sup>Booz Allen Hamilton, McLean, VA, 13 22102, USA, <sup>3</sup>Research Service, VA New York Harbor Healthcare System, Brooklyn, NY, 14 11209, USA, <sup>4</sup>Department of Psychiatry and Behavioral Sciences, SUNY Downstate Health 15 Sciences University, Brooklyn, NY, 11203, USA, <sup>5</sup>Program in Medical and Population Genetics, 16 Broad Institute of MIT and Harvard, Cambridge, MA, 02142, USA, <sup>6</sup>Stanley Center, Broad 17 18 Institute of MIT and Harvard, Cambridge, MA, 02142, USA, <sup>7</sup>Department of Genetics, Harvard Medical School, Boston, MA, 02115, USA, <sup>8</sup>Center for Precision Medicine and Translational 19 20 Therapeutics; VISN 2 Mental Illness Research, Education, and Clinical Center (MIRECC), 21 James J Peters Veteran Affairs Medical Center, New York/New Jersey VA Health Care Network, Bronx, NY, 10468, USA, <sup>9</sup>Center for Disease Neurogenomics; Department of 22 Psychiatry; Friedman Brain Institute; Department of Genetics and Genomic Sciences, Icahn 23 School of Medicine at Mount Sinai, New York, NY, 10029, USA, <sup>10</sup>Center for Data and 24 25 Computational Sciences (C-DACS), VA Cooperative Studies Program, VA Boston Healthcare System, Boston, MA, USA, <sup>11</sup>Center for Data and Computational Sciences (C-DACS), VA 26 Boston Healthcare System, Boston, MA, USA, <sup>12</sup>Office of Research and Development, 27 Department of Veterans Affairs, Washington, DC, 20420, USA, <sup>13</sup>Division of Genetic Medicine, 28 Vanderbilt University Medical Center, Nashville, TN, 37232, USA, <sup>14</sup>Department of Medicine, 29 30 Cardiology Division, Massachusetts General Hospital, Boston, MA, 02114, USA, <sup>15</sup>Cardiovascular Research Center, Massachusetts General Hospital, Boston, MA, 02114, USA, 31 <sup>16</sup>VA Palo Alto Epidemiology Research and Information Center for Genomics, VA Palo Alto 32 Health Care System, Palo Alto, CA, 94304, USA, <sup>17</sup>Department of Medicine, Stanford University School of Medicine, Stanford, CA, 94305, USA, <sup>18</sup>Stanford Cardiovascular Institute, Stanford 33 34 University School of Medicine, Stanford, CA, 94305, USA, <sup>19</sup>VA Palo Alto Health Care System, 35 Palo Alto, CA, USA, <sup>20</sup>Department of Surgery, Stanford University School of Medicine, Stanford, 36 CA, USA, <sup>21</sup>VA Palo Alto Health Care System, <sup>22</sup>Department of Medicine, Division of 37 38 Cardiovascular Medicine, Stanford University School of Medicine, Stanford, CA, USA, <sup>23</sup>Gladstone Institute of Data Science and Biotechnology, Gladstone Institutes, San Francisco, 39 CA, USA, <sup>24</sup>Department of Epidemiology and Biostatistics, University of California San 40 Francisco, San Francisco, CA, USA, <sup>25</sup>Research Service, VA Northeast Ohio Healthcare System, Cleveland, OH, 44106, USA, <sup>26</sup>Cole Eye Institute, Cleveland Clinic, Cleveland, OH, 41 42 44195, USA, <sup>27</sup>Department of Ophthalmology, Cleveland Clinic Lerner College of Medicine of 43 Case Western Reserve University, Cleveland, OH, 44195, USA, <sup>28</sup>Department of Population 44 45 and Quantitative Health Sciences, Case Western Reserve University, Cleveland, OH, 44106,

USA, <sup>29</sup>Department of Ophthalmology and Visual Sciences, University Hospitals Eye Institute,
Cleveland, OH, 44106, USA, <sup>30</sup>Department of Genetics & Genome Sciences, Case Western
Reserve University, Cleveland, OH, 44106, USA, <sup>31</sup>Cleveland Institute for Computational
Biology, Case Western Reserve University, Cleveland, OH, 44106, USA, <sup>32</sup>Department of
Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, 02115, USA,
<sup>33</sup>Present address: BridgeBio Pharma, Palo Alto, CA

- 52 <sup>†</sup> Denotes equal contribution
- 53 <sup>‡</sup> Saiju Pyarajan: saiju.pyarajan@va.gov
- 54 \*Lists of authors and their affiliations appear at the end of the paper.
- 55
- 56

# 57 Abstract

Mosaic loss of chromosome Y (mLOY) is a common somatic mutation in leukocytes of 58 older males. mLOY was detected in 126,108 participants of the Million Veteran 59 Program: 106,054 European (EUR), 13,927 admixed African (AFR), and 6,127 60 Hispanic. In multi-ancestry genome-wide association analysis, we identified 323 61 genome-wide significant loci, 167 of which were novel-more than doubling the number 62 of known mLOY loci. Tract-based ancestry deconvolution resolved local inflation at AFR 63 64 lead SNPs. Transcriptome-wide associations yielded 2,297 significant genes, including seven additional novel genes; integrative eQTL analyses highlighted 51 genes that 65 causally influence mLOY via differential expression. Thirty-two significant traits found in 66 a phenome-wide polygenic score scan were used in Mendelian randomization (MR). 67 68 MR implicated six traits as causal influences on mLOY: triglycerides, high-density 69 lipoprotein, smoking, body mass index, testosterone, and sex hormone-binding globulin; and found influence of mLOY on plateletcrit, prostate cancer, lymphocyte percentage, 70 71 and neutrophil percentage. These results mark a major step forward in our 72 understanding of the genetic architecture of mLOY and its associated risks.

## 74 Introduction

Mosaic loss of Y chromosome (mLOY) is the most common type of mosaic 75 76 chromosomal alteration (mCA), observable in upwards of 40% of males above age 70<sup>1,2</sup>, and 70% of males over 85<sup>3</sup>. mLOY is the most readily detected mCA in 77 leukocytes, which are the primary source of blood-derived DNA. Adaptive immunity 78 79 causes high turnover rates in the hematopoietic stem cell compartment, enabling clonal expansion of mosaic cell subpopulations with selective advantages<sup>4</sup>. Chromosomal 80 81 aberrations in these rapidly expanding cell subpopulations can produce mLOY, though it 82 is unclear if mLOY itself confers selective advantages.

The gene-poor and repetitive-element-rich composition of the Y chromosome 83 84 initially led researchers to believe its role was restricted to spermatogenesis and sex determination<sup>5</sup>. Congruently, mLOY was considered a benign condition, and a 85 consequence of the broader genomic instability that occurs with aging<sup>6</sup>. But in the past 86 decade, epidemiological studies have highlighted associations between mLOY and a 87 broad range of health outcomes; these include all-cause mortality, hematological 88 malignancies and other types of cancer, Alzheimer's disease, type 2 diabetes (T2D), 89 obesity, and cardiovascular disease (CVD)<sup>7</sup>. However, it has yet to be determined 90 91 whether mLOY is a driving causal factor in these conditions, a passenger (i.e. a consequence), or a symptom of a shared, underlying cause, such as genetic 92 93 susceptibility to DNA replication errors, or exogenous exposure to mutagens (particularly via smoking cigarettes)<sup>7,8</sup>. There have also been inconsistent associations 94 with the comorbidities observed across studies, although this may be related to 95 differences in sample collection and mLOY classification methods (e.g. low versus high 96 cell fraction detection) $^{2}$ . 97

medRxiv preprint doi: https://doi.org/10.1101/2024.04.24.24306301; this version posted April 25, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available for use under a CC0 license.

98 The mechanisms of mLOY in producing disease phenotypes are gradually being 99 elucidated. Many genetic risk loci for clonal hematopoiesis of indeterminate potential (CHIP)<sup>9,10</sup> have also been identified as mLOY risk loci<sup>11</sup>, and these two types of 100 mosaicism can co-occur (even in men without observable hematological disease<sup>12</sup>). 101 102 However, the cellular and epidemiological outcomes of CHIP and mLOY appear to be 103 distinct. For example, a study which induced TET2-associated CHIP in mice suggested 104 a mechanistic link to CVD based on expression of inflammatory chemokines in 105 macrophages<sup>13</sup>, while a mouse model of mLOY demonstrated a mechanism of producing CVD through fibrotic deposition in the extracellular matrix<sup>14</sup>. Additionally, 106 107 deletion of chromosome Y by CRISPR-Cas9 produced more aggressive bladder cancer tumors by means of T-cell exhaustion<sup>15</sup>. It has also been suggested that there are bi-108 directional relationships between mLOY and transcriptional dysregulation that lead to 109 differences in disease phenotypes that are dependent on mLOY cell lineage<sup>8</sup>. 110

111 Estimates of single nucleotide polymorphism-based heritability (SNP- $h^2$ ) for 112 mLOY detected via the pseudo-autosomal region 1 (PAR1) are as high as 31.7%, highlighting mLOY as substantially heritable compared to most human traits<sup>1,16</sup>. 113 114 Germline genetics govern many processes which can lead to somatic mCA acquisition 115 and clonal expansion, particularly via cell-cycle regulation, DNA damage response, 116 apoptosis, and susceptibility to cancer. Advances in integrating long-range phasing with 117 genotype have enabled sensitive and accurate identification of mLOY in large-scale 118 cohorts<sup>1</sup>. A genome-wide association study (GWAS) of mLOY status, performed in European ancestry (EUR) UK Biobank (UKB) participants<sup>1</sup>, replicated all 19 previously 119 reported genetic risk loci<sup>17</sup>, including the oncogene *TCL1A*<sup>18</sup>, and identified 137 novel 120

121 loci. A GWAS of mLOY in Biobank Japan (BBJ) using mLRR-Y intensity as a 122 quantitative trait measure identified 46 loci, 35 of which were novel<sup>19</sup>.

In this study we analyzed 544,112 male participants in the Million Veteran 123 124 Program (MVP), a biobank in the Department of Veterans Affairs (VA) healthcare 125 system which combines ancestrally diverse genetic data with extensive electronic health records<sup>20</sup>. In addition to a large EUR cohort, we present the first GWAS of mLOY status 126 127 in African (AFR) and Hispanic/Latino (HIS) ancestries. MVP provides a uniquely valuable resource to perform multi-ancestry mLOY analyses, as it avoids technical 128 129 issues related to genotyping and mosaicism calling that may be introduced by 130 combining data from separate biobanks. Our results highlight the benefits of inclusive 131 population studies in advancing our understanding of mLOY.

132

# 134 **Results**

## 135 mLOY phenotyping and participant characteristics

136 In this study we identified mLOY in MVP participants and performed GWAS with 137 subsequent functional analyses to place our findings in biological context 138 (Supplementary Fig. 1). We used a case-control design to classify mLOY as any 139 detectable mosaicism, using allelic ratio genotyping intensities in PAR1 and PAR2 140 shared by the X and Y chromosomes (Fig. 1a), similar to a previous GWAS in UKB<sup>1</sup>. In 141 MVP, 106,054 of 400,970 (26.4%) EUR men (median age 66) showed evidence of 142 mLOY. A lower prevalence of mLOY was observed in AFR (13,927 of 99,103; 14.1%; 143 median age 60) and HIS (6,127 of 44,039; 13.9%; median age 60) (Supplementary 144 Data 1). The prevalence of mLOY increased with age, from 10% among participants aged 50-60 to upwards of 50% in octogenarians (Fig. 1b-c). mLOY cell fraction 145 146 percentage increased with age across all ancestries (Supplementary Fig. 2a). Lifetime 147 smoking was associated with a higher odds ratio (OR) of mLOY (adjusted for age and 148 age-squared) at 1.33 [95% confidence interval (CI)=1.30,1.35] in EUR: this finding was 149 consistent across AFR and HIS (Supplementary Data 1), and with previous reports from UKB<sup>1</sup>. Current and former smoking status were also associated with higher mLOY cell 150 151 fraction percentages (Supplementary Fig. 2b).



152

153 Fig. 1. mLOY in the Million Veteran Program. a, Median genotyping probe intensity log R ratio (LRR) vs. phased B 154 Allele Frequency (BAF) in the pseudo-autosomal regions (PAR) 1 and 2. b, Percentage of individuals with mLOY per tenyear age bin for MVP European (EUR), African (AFR), and Hispanic (HIS) cohorts. Error bars represent 95% confidence 155 intervals. c, Density of age distribution in all MVP mLOY cases and controls. d, Manhattan plots show the -log10(P) for 156 associations of genetic variants with mLOY in the multi-ancestry meta-analysis. Novel mLOY index variants and variants 157 within  $\pm$  50 Kb are highlighted in red. The red line indicates the genome-wide significance threshold ( $P < 5 \times 10^{-8}$ ). The grey 158 log-scale 159 dotted represents transition linear the line а from to on y-axis.

## 160 Genome-wide significant associations

We performed a GWAS for mLOY case-control status in each ancestry group 161 (Supplementary Data 2). We identified 336 conditionally independent genome-wide 162 significant (GWS; P<5×10<sup>-8</sup>) signals in 203 distinct loci for EUR, 50 signals in 46 loci for 163 164 AFR, and 17 signals in 15 loci for HIS (Supplementary Fig. 3a-c, Supplementary Data 3-165 5). Of the EUR signals, 220 were within 1Mb of a previously reported mLOY index variant<sup>17,19</sup>, including 148 of the 156 previously identified in UKB<sup>1</sup>, and 116 were novel. 166 In a variant-level replication of 327 EUR signals that were available in UKB<sup>1</sup>, all but one 167 168 (rs925301) had the same effect direction (Supplementary Data 3, Supplementary Fig. 4a). Of the 116 novel MVP signals, 17 had  $P < 1 \times 10^{-5}$  and 97 had P < 0.05 in UKB<sup>1</sup>. 169

The most significant association signals in MVP EUR and HIS were in TCL1A; in 170 EUR, we identified the same *TCL1A* lead variant as in previous GWAS<sup>1,18</sup> (rs2887399; 171 OR=0.708 [0.697, 0.719]; P=3.18×10<sup>-419</sup>; Supplementary Fig. 5a). The strongest effect 172 of an allele in EUR was at TP53, an oncogene associated with mCAs and CHIP 173 (rs78378222; OR=1.664 [1.584, 1.749]; P=1.44×10<sup>-90</sup>). In AFR, the most significant 174 175 association was in RPN1 at rs113336380, which has a minor allele frequency (MAF) of 176 ~6% in AFR and <0.01% in EUR (Supplementary Fig. 5b). Effect directions were largely concordant between EUR and AFR associations (r=0.656,  $P=1.13\times10^{-46}$ ), with the 177 178 exception of a group of novel EUR variants that were not significant in AFR, and rs6018599 (GGT5/CABIN1), which was GWS only in AFR (Supplementary Fig. 4b). 179 180 Four additional GWS novel signals were specific to AFR: MPL, NKX2-3, ETV6, and 181 BLCAP (Supplementary Fig. 6; Supplementary Data 4). All 17 HIS signals were GWS in EUR (Supplementary Data 5); 15 of these were GWS in AFR, and all HIS signals were 182

GWS in UKB<sup>1</sup>. Effect direction at significant HIS signals between HIS and EUR were consistent (Supplementary Fig. 4c). We improved our variant selection by fine-mapping and estimating credible sets of candidate causal variants in EUR and AFR. In EUR, we found 11,242 variants in 334 high-quality credible sets, with a median of 8.5 variants per credible set (Supplementary Data 6). In AFR, we found 533 variants in 45 high-quality credible sets, with a median of 5 variants per credible set (Supplementary Data 7).

189 We extended our association analyses for all ancestries to a genotype panel enriched in protein-altering rare variants (MAF<0.001)<sup>21</sup>, and identified four novel GWS 190 191 variants in EUR (Supplementary Data 8), including a frameshift mutation at DCXR:c.583del (p.His195fs), and somatic missense mutations in DNMT3A (R882H), 192 193 JAK2 (V617F), and IDH2 (R140Q), which are known to be associated with hematologic malignancies such as CHIP and acute myeloid leukemia (AML)<sup>22,23</sup>. The estimated 194 195 effects of these rare variants were negative and, consistent with expectation, stronger 196 than those of common variants (Supplementary Fig. 7).

197 Fixed effects (FE) multi-ancestry meta-analysis of the three MVP ancestry 198 groups identified 298 GWS loci, including 157 novel loci, 42 of which did not reach GWS 199 in any individual ancestry (Fig. 1d; Supplementary Fig. 3d; Supplementary Data 9). After 200 meta-analysis there remained 8 EUR loci and 2 AFR loci that were GWS only within 201 their respective ancestries. Of the 42 added meta-analysis novel lead variants, 32 had P<0.05 in UKB<sup>1</sup> and two had P<1×10<sup>-5</sup>. For all 298 meta-analysis lead variants, 211 202 were available in the BBJ mLOY GWAS<sup>19</sup>; though BBJ used a less sensitive 203 204 quantitative mLOY measure (logarithm of R ratio) as opposed to our case-control designation, the effect of 188 of the 211 variants were aligned, including all 88 BBJ 205

variants with *P*<0.01 (Supplementary Fig. 4d). BBJ<sup>19</sup> shared 28 GWS variants with our meta-analysis (Supplementary Data 9). Within MVP meta-analysis index variants, rs2887399 (*TCL1A*) remained the most significant association (*P*= $5.25 \times 10^{-459}$ ). We also performed random effects (RE) meta-analyses using the Han-Eskin method (RE2)<sup>24</sup>, and observed similar P-values to FE (Supplementary Data 9).

## 211 Tract-based association analysis for AFR

212 We used local ancestry inference and performed a GWAS using the Tractor method<sup>25</sup> as a secondary analysis to resolve ancestry-specific signals in AFR 213 214 (Supplementary Fig. 8). Signals resulting from recent admixture with large allele 215 frequency differences between ancestries can be disentangled with this method; we 216 highlight two AFR loci to illustrate. First, inflation due to admixture was observed at 217 20g11.21 near BCL2L1 (Fig. 2a). Because global adjustment for ancestry by including 20 principal components (PCs) in this GWAS model did not sufficiently resolve this 218 219 locus (Fig. 2b), we inferred that the inflation was due to the differences in risk allele 220 frequency at the lead SNP rs2376992 across ancestral haplotypes (51% AFR vs 22% 221 EUR, Supplementary Fig. 9a) at this large effect size locus (OR=0.798 [0.776, 0.820];  $P=1.7\times10^{-56}$ ). 222

This was further supported by 20q11.21 having a highly significant difference in AFR and EUR haplotype dosages ( $P=5.6\times10^{-29}$ ; Fig 2a). The secondary cluster of significant variants downstream of *BCL2L1* was resolved in the AFR tract relative to the EUR tract (Fig. 2cd; Supplementary Fig. 9b). Strikingly, a meta-analysis of the AFR and EUR tracts for chromosome 20 yielded a genomic control ( $\lambda$ ) of 1.08, as compared to  $\lambda=1.40$  in the conventional AFR GWAS. We then fine-mapped the smaller credible set

of SNPs identified in the AFR tract. The risk allele of the SNP with the highest posterior probability, rs2376992, is found in a known promoter region for *BCL2L1* (ENSR00001234227).

At 18q12.3 (*SETBP1*), a known EUR mLOY locus, we observed a complex LD structure with multiple causal SNPs which inhibited fine mapping of this locus in AFR (Supplementary Fig. 9c). Tract-based association analysis resolved the overlapping LD structures, and revealed the primary AFR signal at rs4414576 (Supplementary Fig. 9d); this allele had 32% frequency in AFR and only 3% in EUR. The EUR tract at this locus (Supplementary Fig. 9e) had a similar structure to the EUR GWAS (Supplementary Fig. 9f).

Additionally, we performed a tract-based analysis in HIS mLOY cases (Supplementary Fig. 10). In this model we accounted for the two main ancestral contributors, EUR and Native American (NAT). Similar to AFR, we found the most significant differential enrichment of haplotypes at 20q11.21 (Supplementary Fig. 11). This locus in HIS is inflated by the low frequency of the lead variant rs2376992 in NAT haplotypes (~0.3%, compared to 49% in AFR and 78% in EUR).



Fig. 2. Global- vs. local-ancestry-adjusted GWAS of mosaic loss of Y in admixed African (AFR) ancestry Million Veteran Program participants. a, Miami plot showing conventional AFR GWAS globally adjusted by principal components (top) and AFR vs. European (EUR) haplotype dosage enrichment (bottom). b, At 20q11 (*BCL2L1*) we observed inflation due to local ancestry. This inflation was resolved by separating the AFR and EUR tracts as shown in c and d.

## 251 Gene set, tissue and cell-type enrichment of mLOY genes

Using the multi-ancestry meta-analysis, genes mapped within 10Kb of GWS 252 multi-ancestry LD blocks were significantly enriched for two GTEx v8 general tissue 253 types, blood ( $P=3.11\times10^{-10}$ ) and spleen ( $P=3.85\times10^{-6}$ ), consistent with expectations of 254 mLOY primarily occurring in leukocytes (Supplementary Fig. 8a). These mapped genes 255 were then used to compare gene set enrichment in all loci (Supplementary Data 10) and 256 257 novel loci (Supplementary Data 11). The most highly enriched Gene Ontology Biological 258 Process (GO BP) for novel loci was Cell Cycle (47 novel loci), indicating genes involved 259 in the replication and segregation of genetic material and cell division; this was in 260 addition to 64 Cell Cycle known loci. Hallmark gene sets, representing well-defined 261 biological processes, were used as a framework for categorization of novel mLOY loci. Novel genes associated with the G2/M checkpoint were the most significantly enriched 262 with 18 novel loci and FDR-adjusted *P*-value (adj*P*)= $3.16 \times 10^{-6}$ . followed by the 263 PI3K/AKT/mTOR (10 novel loci;  $adj P=1.38 \times 10^{-4}$ ), and heme metabolism (11 novel loci; 264  $adiP=9.07 \times 10^{-3}$ ) gene sets (Supplementary Fig. 12bc). 265

We then tested for enrichment of EUR index variants located in cell-specific open 266 chromatin regions, by intersecting our genetic associations with data from two catalogs 267 of the human epigenome that profile major human body lineages and blood cell 268 lines<sup>26,27</sup>. At the tissue level, we found significant enrichment only in myeloid/erythroid 269 cells (Supplementary Fig. 13a;  $adi P=1.2 \times 10^{-4}$ ). Of the blood cell lines, the highest 270 enrichment was measured for multipotent progenitors (MPP:  $adiP=6.4 \times 10^{-4}$ ) and their 271 272 subsequent differentiation stages, i.e. common myeloid progenitors (CMP; adj P=1.2×10<sup>-</sup> <sup>3</sup>) and lymphoid-primed multipotent progenitors (Supplementary Fig. 13b; LMP; BH-273 corrected  $P=1.1\times10^{-3}$ ), thus supporting the established role of mLOY genetic effects on 274

blood cell differentiation<sup>19</sup>. Interestingly, among the six differentiated cell types 275 276 encompassing myeloid, erythroid, and lymphoid cells (Supplementary Fig. 13b), only 277 erythroid cells exhibited significant enrichment (adjP=0.017). This enrichment pattern of 278 mLOY-related effects on differentiating blood cells contrasts starkly with other diseases 279 characterized by perturbations in immune responses, chronic inflammation, or 280 autoimmune mechanisms, such as Crohn's disease, rheumatoid arthritis, systemic 281 lupus erythematosus, multiple sclerosis or Alzheimer's disease (Supplementary Fig. 282 13c).

## 283 eQTLs from single-cell RNA-seq

284 To identify how SNPs associated with mLOY in EUR associate with gene 285 expression in immune cells, we used a recently published expression quantitative trait 286 loci (eQTL) dataset derived from single-cell RNA-seq data across different immune cell populations<sup>28</sup>. Across the fourteen immune cell subsets, we found that 197 of 327 EUR 287 288 mLOY SNPs spanning 251 eQTLs reached at least nominal significance (P<0.05; 289 Supplementary Data 12). Of these, 34 eQTLs (22 unique genes; 8 unique SNPs) reached the significance threshold corrected for multiple testing ( $P < 1.1 \times 10^{-5}$ ); 20 of 290 291 these eQTLs were associated with two SNPs in the major histocompatibility complex 292 (MHC) region (6p22.1 to 6p21.3).

293

### 294 Multi-tissue TWAS and SMR

295 We linked our EUR GWAS signals with functional gene units in a multi-tissue 296 transcriptome-wide association study (TWAS). Our TWAS leveraged 43 tissue models

including STARNET Blood<sup>29</sup> and a high-powered dorsolateral prefrontal cortex (DLPFC) 297 dataset<sup>30</sup> (Supplementary Data 13); this yielded 2,297 unique significant gene features 298 at P<sub>Bonferroni</sub><0.05. In the STARNET blood model, 117 features were significant at 299 300  $P_{Bonferron} < 0.05$ , including one novel gene that did not appear in GWAS, MED19, a 301 component of the Mediator complex involved in the regulated transcription of RNA 302 polymerase II-dependent genes (Supplementary Data 14, Supplementary Fig. 14a). In 303 the DLPFC model, 191 features were significant at  $P_{Bonferroni} < 0.05$ ; the novel genes identified in DLPFC were IL21R, (cytokine receptor for interleukin 21) and COX7A2L 304 (Supplementary Data 15). All tissues were then meta-analyzed using ACAT<sup>31</sup>, yielding a 305 306 total of 683 genes with P<sub>Bonferroni</sub><0.05 (Supplementary Data 16, Supplementary Fig. 14b). ACAT revealed an additional five novel genes: PSTPIP2, CCNK, RAD54L2, 307 PARP10, and G3BP1, plus the non-coding gene LINC01933 and pseudogene 308 309 AC091982.1. We found that mLOY-associated gene expression was highly correlated 310 across the imputed transcriptomes of all tissues (Supplementary Fig. 15).

We further performed summary-data-based Mendelian randomization (SMR) experiments to provide support for inference of causality. Across 33 tissue types, we identified 1,870 significant genes with *FDR*<0.05 and *P<sub>HEIDI</sub>* $\geq$ 0.05, and of these, 234 were identified in Blood SMR (Supplementary Data 17). SMR in Blood provided causal support for 23 significant genes (20%) from STARNET Blood, and 51 genes (7%) across the combined TWAS findings from STARNET Blood, DLPFC, and ACAT metaanalysis (Supplementary Fig. 16).

## 318 Genetic correlations of mLOY

319 Genetic correlations ( $r_a$ ) between mLOY in EUR and 750 traits were tested 320 (Supplementary Data 18). At the multiple testing corrected significance threshold  $P < 6.67 \times 10^{-5}$ , 36 traits were significantly correlated. Many metabolite measures had a 321 322 significant negative  $r_{\alpha}$  with mLOY at this threshold, including particle sizes of cholesterol, 323 phospholipids, triglycerides, and total lipids in VLDL, which had  $r_{\rm q}$  ranging from -0.34 (se 324 = 0.07) to -0.28(0.06). Maternal smoking around birth was positively correlated at  $r_{q}$  = 325 0.12 (0.03). Significant and negative  $r_{g}$  were observed for hip circumference and the 326 related anthropometric measures obesity class 2, and BMI.

## 327 Association of PGS Catalog-based polygenic scores with mLOY

We calculated polygenic scores (PGS) for every trait in the PGS Catalog<sup>32</sup>, for all 328 329 EUR subjects, and performed a phenome-wide scan for the association of normalized 330 PGS scores with mLOY case-control status (PGS-WAS) to discover shared genetic etiology (Supplementary Data 19). A total of 2,644 scores corresponding to 562 331 332 uniquely mapped traits in the Experimental Factor Ontology (EFO) were tested; we 333 found 82 mapped traits significant after multiple testing correction ( $\alpha$ =0.05/562). Many of 334 the most significant traits were blood measures, including increased platelet crit (1.11 335 [1.10,1.12]), leukocyte count (1.07 [1.06,1.08]), monocyte count (1.07 [1.06,1.08]), and neutrophil count (1.06 [1.05,1.07]), and decreased mean corpuscular hemoglobin 336 337 concentration (0.94 [0.93,0.95]). Several metabolic traits were also associated, such as 338 triglycerides (0.925 [0.914,0.935]), HDL (1.06 [1.04,1.07]), BMI (0.945 [0.94,0.96]), 339 SHBG (1.05 [1.04,1.06]), T2D (0.93 [0.91,0.94]), as well as smoking status (1.05 340 [1.04,1.06]).

## 341 Multi-trait conditioning of mLOY on cigarettes per day

In MVP participants we observed a strong observational association of mLOY 342 with smoking, as well as in the PGS-WAS. To parse out the residual effects of smoking 343 344 on mLOY susceptibility, we conducted multi-trait-based conditional and joint association analysis<sup>33</sup> (mtCOJO) in EUR, conditioning on cigarettes per day<sup>34</sup>. Across the genome, 345 346 only the 15q25 region was primarily impacted by the conditional analysis (Supplementary Fig. 17a). This signal, which was GWS for mLOY in the primary GWAS, 347 348 was attenuated towards the null after conditioning (Supplementary Fig. 17bc). This 349 locus contains a well-known cluster of smoking-related genes, including CHRNA5 which 350 encodes a nicotinic acetylcholine receptor subunit that has been frequently associated 351 with smoking in GWAS<sup>35</sup>.

## 352 Polygenic risk and BMI influence penetrance of mLOY in an age-dependent manner

Because we observed a significant negative genetic correlation and PGS-WAS 353 association between mLOY and BMI, an association that has also been reported in 354 previous studies<sup>36,37</sup>, we sought to examine the prevalence of mLOY in MVP-EUR as a 355 function of age, BMI, and PRS decile derived from UKB<sup>1</sup>. In all age bins, we observed 356 that decreasing BMI and increasing PRS were associated with higher mLOY prevalence 357 358 (Fig. 3a). Overall, our results suggest that this association between mLOY and BMI is 359 not merely confounded by the strong age-dependence of mLOY. We also observed a stronger genetic correlation between mLOY and BMI in MVP ( $r_{a}$ =-0.110 (0.026)) than 360 361 previously reported in UKB ( $r_q$ =-0.052 (0.032); Supplementary Data 18); this may be a 362 result co-morbidities **MVP** UKB. of greater in the cohort versus



363

Fig. 3. Mosaic loss of Y by PRS decile and Mendelian randomization (MR). a, Percentage of individuals with mLOY by PRS decile, stratified by age decile (plot grid) and BMI range (color). b, Forest plot showing exposure traits with significant results from random effects inverse-variance weighted (RE IVW) MR and corresponding multivariable MR (MVMR) with cigarettes per day as an additional exposure, on mLOY outcome in Million Veteran Program Europeans. c, Significant results from RE IVW MR and MVMR considering mLOY exposure on trait outcomes. CI, confidence interval.

## 369 Univariable and multivariable Mendelian randomization

370 We used the significant PGS Catalog trait associations with mLOY to inform the 371 selection of 32 traits for MR in the EUR cohort, using male-only summary statistics 372 where available, to infer the direction of causality between these exposures and mLOY. 373 Random effects inverse-variance weighted (IVW) forward MR supported six significant 374 traits ( $\alpha$ =0.05/32) with non-significant MR-Egger intercept (*P*≥0.05) as causal influences on mLOY: triglycerides, high-density lipoprotein (HDL), cigarettes per day<sup>38</sup>, body mass 375 index (BMI), total testosterone, and sex hormone-binding globulin (SHBG) (Fig. 3b; 376 377 Supplementary Fig. 18; Supplementary Data 20). Reverse MR indicated a significant causal influence of mLOY on plateletcrit, lymphocyte percentage, prostate cancer, and 378 379 neutrophil percentage (Fig. 3c; Supplementary Fig. 19; Supplementary Data 21). Our 380 finding that mLOY status increases the risk of prostate cancer (OR=1.061 [1.031, 1.092]) is in agreement with a recent study using the PRACTICAL Consortium<sup>39</sup>. 381

Because mLOY is strongly associated with smoking, and because the pleiotropic 382 383 effects of tobacco smoking instruments have large effects on human health, we conducted multivariable MR using cigarettes per day<sup>38</sup> as a second exposure in the 384 models of significant forward and reverse MR associations (Fig. 3bc; Supplementary 385 Data 22). The direct effect of each exposure on their respective outcomes in 386 multivariable MR were highly similar to the univariable model, and remained significant, 387 with the exception of SHBG (P=8.92×10<sup>-3</sup>). Additionally, SHBG had P>0.05 in all of MR-388 Egger, weighted-median and weighted-mode sensitivity analyses, and so this 389 390 association is considered less robust than those of the other traits. Overall, multivariable

391 MR demonstrates that the inferred causality identified in univariable MR was

392 independent of cigarette smoking.

# 393 Discussion

394 In this multi-ancestry meta-analysis we have more than doubled the number of 395 genetic loci associated with mLOY, adding 167 novel loci. The large number of new mLOY cases (N=126,108) that powered our discovery was enabled by several factors. 396 First, we utilized the MVP biobank<sup>20</sup>, which consists of mostly aging males, many of 397 whom were current or previous cigarette smokers. Next, the MoChA<sup>4,40</sup> software, which 398 can detect chromosome-length events at a lower cell fraction threshold than in previous 399 GWAS<sup>1,18</sup>, enabled the inclusion of cases from early stages of mosaicism proliferation. 400 401 Lastly, the sample size achieved by combining cohorts into a large multi-ancestry meta-402 analysis increased the number of GWS loci compared to the largest individual cohort 403 (EUR) by about 50%. This mLOY GWAS is the first to include AFR and HIS 404 populations: we identified 5 AFR-specific signals, and additionally found 17 loci in HIS 405 which were replicated in EUR. An additional benefit of MVP is that the extensive electronic health records within this biobank enabled a thorough post-GWAS exploration 406 407 of the relationships of mLOY with other phenotypes.

We found that cell cycle was the most highly enriched Biological Process (GO) 408 for genes positionally mapped to novel loci (47 novel loci), strengthening the 409 410 mechanistic suppositions of previous studies that reduced cell cycle efficacy is a primary driver of mLOY<sup>1,17,18</sup>. The most significant gene set in novel loci was G2/M 411 checkpoint, responsible for blocking damaged and incompletely replicated DNA from 412 progressing through the cell cycle. The G2/M checkpoint is regulated in part by p53<sup>41</sup>, a 413 tumor suppressor involved with mLOY, CHIP, and other mCAs<sup>3</sup>. The next most highly 414 enriched novel gene set, the PI3K/AKT/mTOR pathway (13 novel loci), is a regulator of 415

416 cell growth and survival, particularly in the context of cancer progression<sup>42</sup>. The Heme 417 Metabolism gene set (11 novel loci) also includes genes involved in erythroblast 418 differentiation; the expansion of leukocytes in mLOY has previously been associated 419 with reduced erythrocytes<sup>43</sup>. Additionally, Xenobiotic Metabolism (11 novel loci) of 420 foreign substances, including cigarettes, environmental pollutants, and chemotherapy 421 drugs, has also been strongly associated with mCAs in previous studies<sup>11,44,45</sup>.

422 Our forward MR associations were all directionally consistent with a recent observational study in UKB<sup>46</sup>; additionally, their MR analysis of SHBG is in agreement 423 with our finding that SHBG exerts a positive causal influence on mLOY in forward MR<sup>46</sup>. 424 425 Interestingly, higher triglycerides had a protective causal influence on mLOY (OR=0.84 [0.80, 0.89]; *P*=5.38×10<sup>-11</sup>) while higher HDL conferred risk (OR=1.10 [1.05, 1.15]; 426  $P=3.71\times10^{-5}$ ). Though this is opposite of the pattern commonly observed in CVD, 427 previous MR studies<sup>47</sup> have identified robust associations between HDL and increased 428 risk of breast cancer.<sup>48,49</sup> and between triglycerides and decreased risk of breast 429 cancer.<sup>50</sup>. Triglycerides also had significant negative genetic correlation and PGS-WAS 430 431 score with mLOY, and HDL had significant positive PGS-WAS score with mLOY. Two novel mLOY-risk-increasing SNPs are also lead SNPs for triglycerides, at BUD13<sup>51</sup> and 432 SNX17<sup>52</sup>. Overall, more studies are necessary to uncover the mechanisms underlying 433 434 this phenomenon. We also found that red blood cell distribution width (RDW) exerts a positive causal influence on mLOY that was nearly significant at the multiple testing 435 threshold (OR= 1.11 [1.04, 1.18]; P=0.002). RDW is an index which reflects impaired 436 437 erythropoiesis and abnormal red blood cell survival. Multiple mLOY-associated cyclin genes are related to RDW mechanism: CDK6 (novel) promotes G1/S transition, CCND3 438

(known) encodes cyclin D3, alters cell cycle progression and reduce control of cell
size<sup>53</sup>, and novel TWAS gene *CCNK* is a cyclin activator.

441 In addition to replicating the result that mLOY can increase risk of prostate cancer<sup>39</sup>; reverse MR indicated a significant causal influence of mLOY on increased 442 443 plateletcrit, increased neutrophil percentage, and decreased lymphocyte percentage. 444 The directions of these relationships are concordant with the previous observational report<sup>43</sup>. Neutrophil-to-lymphocyte ratio (NLR) in peripheral blood is an emerging 445 prognostic factor in many diseases, especially cancers<sup>43,54</sup>, and elevated NLR indicates 446 447 neutrophilic inflammatory response, impaired cell-mediated immunity, and is suggestive of overall poor prognosis<sup>43,54,55</sup>. 448

449 Our study was not without limitations. First, we performed a cross-sectional study 450 at a single time point. Future studies may benefit from a prospective study design as mLOY is associated with aging<sup>56</sup>. Additionally, it has been shown in MDS that young 451 and old cases have distinct genetic landscapes<sup>57</sup>, which should also be examined in 452 453 future studies. We also did not consider the effects of environmental exposures aside 454 from smoking and BMI. Veterans may be disproportionately exposed to pollutants and other toxins over their lifetimes compared to the general public<sup>58</sup>. This could have 455 456 caused our mLOY prevalence estimates to be inflated (although they were in agreement 457 with previous studies), and could exacerbate potential gene-environment interactions on 458 mLOY risk. Next, we did not distinguish between high- and low-cell fraction of mLOY when defining cases. Our classification method could detect very low cell fractions as 459 opposed to most existing studies which used high cell fraction detection methods such 460 461 as intensity thresholding (i.e. on mLRR-Y). Next, our analysis evaluated DNA from

peripheral blood mononuclear cells (PMBCs) only, and did not consider mLOY from
other tissues. Finally, as always, significant GWAS results are associations, and not
proof of causal disease mechanisms.

We found broad concordance across multiple ancestral populations in our metaanalysis, as well as with the previous BBJ cohort<sup>19</sup>, strengthening the generalizability of our findings. Future multi-ancestry meta-analyses may enable increased power and associated loci discovery. The new risk loci identified in this study will lead to improved genetic risk prediction, diagnosis, and understanding of the cellular mechanisms surrounding mLOY.

## 472 Methods

## 473 Ethics/study approval

474 All participants provided informed consent, and the studies conducted at 475 participating centers received approval from the Institutional Review Boards.

## 476 Genotyping, imputation, and ancestry assignment

Genomic data processing was performed for >650,000 MVP participants 477 (releases 1-4). Genotyping was performed using the Thermo Fisher MVP 1.0 Affymetrix 478 479 Axiom Biobank array<sup>21</sup>. Samples with >2.5% missing genotype calls, excess 480 heterozygosity, those that were potential duplicates, and those with discordance 481 between genetic sex and self-identified gender, were excluded. SNPs with missingness >5% or minor allele frequency (MAF) that deviated by >10% from the 1000 Genomes 482 Project Phase 3 (1KGP3) data<sup>59</sup> were excluded. Pairwise genetic relatedness was 483 estimated using KING<sup>60</sup>; one individual was removed at random from each pair of first-484 degree relatives, preferentially retaining cases from case-control pairs. Ancestry was 485 algorithmically assigned using HARE (Harmonized ancestry and race/ethnicity)<sup>61</sup>, which 486 487 incorporates self-reported race and ethnicity data to train a genetic ancestry classifier. 488 Using HARE, we grouped 544,112 male participants in MVP according to European (EUR), African (AFR), or Hispanic (HIS) ancestry. 489

Genotypes were statistically phased over the entire cohort using SHAPEIT4 version 4.1.3<sup>62</sup> with PBWT depth 8. Phased genotypes were imputed to the African Genome Resources (AGR) reference panel<sup>63</sup> using Minimac 4. The AGR panel consists of all 5,008 1KGP3 haplotypes and an additional 2,862 haplotypes from unrelated pan-African samples. As AGR contains biallelic SNPs only, a second imputation was

performed using 1KGP3, with indels and other complex variants merged into the
primary imputation. Imputation for chrX for EUR, AFR, and HIS was performed using
TOPMed (hg38); significant loci on chrX were lifted over<sup>64</sup> to hg19 for reporting.

498 Detection of mLOY using long-range haplotype phase

We used SHAPEIT4<sup>62</sup> to infer haplotypes from array genotypes for the whole MVP cohort and we utilized MoChA<sup>4,40</sup>, an extension to the BCFtools software suite<sup>65</sup>, to infer the presence of mLOY by detecting shifts in allelic ratios between the phased PAR1 and PAR2 haplotypes, similar to what was done previously in UKB<sup>1</sup>. This methodology allows to infer the presence of mLOY for cell fractions as low as ~1%. Cell fraction was estimated from B allele frequency deviation (bdev) using the formula 4\*bdev / (1+2\*bdev).

506 *GWAS* 

Presence or absence of any detectable mLOY cell fraction was used as a case-507 control trait in all analyses, performed using male participants only. Single variant 508 genome-wide association testing was carried out with REGENIE v1.0.6.7<sup>66</sup> using age, 509 510 age-squared, and twenty PCs. REGENIE step 1 was performed using leave-one out 511 cross validation (--loocv). Approximate Firth likelihood ratio test (LRT) was applied as 512 fallback for associations with P<0.05, with SE computed based on LRT where applied. 513 We kept common variants with minor allele frequency (MAF) ≥0.1% and minimum 514 imputation quality (INFO) of 0.3. Two significant chrX loci in PAR1 (rs2857319) and 515 PAR2 (rs306890), both near the boundary with the nonPAR, had large frequency 516 differences between X and Y chromosomes in the Genome Aggregation Database

(gnomAD v3.1.2). These loci were removed after determining the mLOY allele was
exclusively in high cell fraction participants, indicating likely genotyping error
(Supplementary Fig. 20). For chrY, genotype calls were tested for associations using
PLINK2 (alpha v20211217), with Firth correction applied to all variants.

521 Within each ancestry group, we performed conditional association analyses 522 using Genome-wide Complex Trait Analysis multi-SNP-based conditional and joint 523 association analysis (GCTA-COJO)<sup>67</sup> to identify secondary association signals at 524 associated loci, using LD reference panels consisting of 100,000 randomly selected 525 participants for EUR and AFR, and all 52,183 participants in HIS. COJO SNPs with  $r^2 \ge$ 526 0.05 were iteratively retained based on lowest *P*-value.

527 For replication, MVP-EUR COJO association signals were compared to summary 528 statistics from the previous mLOY GWAS in UKB<sup>1</sup>. An updated version of chrX UKB 529 summary statistics were utilized for this comparison ( $N_{case}=40,466$ ;  $N_{control}=146,066$ ; 530 personal.broadinstitute.org/giulio/mLOY); MACH R2 values were considered for variant 531 quality in lieu of INFO scores.

532 Fine-mapping

We performed Bayesian fine-mapping of each genome-wide significant locus in 533 the EUR and AFR using SuSiE<sup>68</sup>. Pairwise SNP correlations were calculated directly 534 535 from imputed dosages on 320,831 European-ancestry samples in MVP using LDSTORE 2.0<sup>69</sup>. The maximum number of allowed causal SNPs at each locus was set 536 10 default 537 (the used the FinnGen fine-mapping pipeline: to in Fine-mapping https://github.com/FINNGEN/finemapping-pipeline). 538 regions which overlapped the major histocompatibility complex (MHC; chr6:25,000,000-34,000,000) 539

were excluded. High quality credible sets were defined as those with minimum  $r^2 < 0.5$ between variants (88/422 discarded in EUR, 24/69 in AFR).

## 542 Rare variant analysis

543 We conducted association analyses for rare variants in each MVP ancestry 544 group using REGENIE and the same covariates as in standard GWAS. We considered only variants genotyped on the MVP 1.0 array<sup>21</sup>, which is enriched in protein-altering 545 rare variants, and applied the Rare Heterozygous Adjustment algorithm<sup>70</sup> to improve the 546 547 positive predictive value of rare genotype calls. We further restricted the included 548 markers to directly genotyped ultra-rare variants (MAF<0.1% in controls) classified as "high-impact"<sup>71</sup>. Rare variants were categorized as somatic or germline based on allele 549 balance for heterozygotes obtained from the Genome Aggregation Database 550  $(qnomAD)^{72}$ . 551

## 552 GWAS multi-ancestry meta-analysis

MVP EUR, AFR, and HIS cohorts were filtered by INFO>0.5 to retain only high 553 guality variants, and meta-analyzed for fixed effects using METAL (v20200505), 554 555 weighting effect sizes by the inverse of their corresponding standard errors. Only variants present in two or more ancestries were retained. Loci were defined for all 556 cohorts (including counting loci in UKB<sup>1</sup> for comparison purposes), using the two-stage 557 558 "clumping" procedure implemented in the Functional Mapping and Annotation (FUMA) platform<sup>73</sup>. In this process, genome-wide significant variants are collapsed into LD 559 blocks ( $r^2 > 0.6$ ) and subsequently re-clumped to yield approximately independent 560  $(r^2 < 0.1)$  signals; adjacent signals separated by <250kb are ligated to form independent 561

562 loci. Novel variants were defined as COJO signals in independent ancestry cohorts, or 563 meta-analysis index variants, located >1Mb from a previously reported GWAS 564 association with mLOY. For the multi-ancestry meta-analysis, we further performed a 565 sensitivity analysis using the Han-Eskin random effects model (RE2) in METASOFT v2.0.1<sup>24</sup>. FE and RE2 *P*-values at top loci were highly similar. We compared our meta-566 analysis lead variants to UKB<sup>1</sup> as described above and to BBJ<sup>19</sup> where available. BBJ 567 568 reported their results as mLRR-Y intensity thresholding as a proxy for mean Y 569 chromosome dosage in circulating blood cells of subjects.

## 570 Local ancestry deconvolution and tract-based GWAS

571 We inferred local ancestry within AFR participants assuming two-way (AFR/EUR) admixture, and within HIS assuming three-way (AFR/EUR/NAT) admixture. The 1000 572 573 Genomes YRI (N=108) and CEU (N=99) populations, were used as the AFR and EUR reference, respectively, and 43 Native American samples from Mao et al.<sup>74,75</sup> were used 574 as the NAT reference. We used RFMIX<sup>76</sup> version 2 to generate local ancestry calls for 575 phased genotypes. We then extracted ancestry-specific dosages from the imputed data 576 into PLINK 2.0-compatible files<sup>77</sup> using custom scripts based on the Tractor workflow<sup>25</sup>. 577 578 For the AFR analysis, EUR-specific dosages were put into a PGEN file, and African-579 specific dosages and EUR haplotype counts were interlaced in a zstandard-compressed 580 table. For the HIS analysis, EUR-specific dosages were put into a PGEN file, with 581 African and NAT-specific dosages and EUR and AFR haplotype counts interlaced into a 582 zstandard-compressed table. We used these files to conduct a local ancestry-aware 583 GWAS using the PLINK 2.0 local covariates feature, obtaining ancestry-specific marginal effect size estimates. 584

## 585 Gene set, tissue and cell type enrichment analysis

586 FUMA GENE2FUNC<sup>73</sup> was performed using multi-ancestry meta-analysis 587 summary statistics in genes that were positionally mapped to significant variants (within 588 10 Kbp) excluding the MHC gene region; this analysis was also stratified by GWAS 589 locus novelty. Benjamini-Hochberg (FDR) was used as the gene set enrichment multiple 590 test correction method. Hallmark gene sets<sup>78</sup> were used to categorize genes.

To further evaluate whether the genomic loci implicated in mLOY were enriched in any particular cell type, we intersected common mLOY risk variants with broad and blood-specific epigenomic catalogs of cell-specific open chromatin<sup>26,27</sup> using an LD score partitioned heritability approach (LDSC)<sup>79</sup> (Fig. S\_ctype\_a-b). For the broad epigenome catalog encompassing various human tissues<sup>26</sup>, we re-used the open chromatin regions associated with each tissue from the lists provided by the creators of the atlas

598 (https://www.meuleman.org/DHS\_Index\_and\_Vocabulary\_hg38\_WM20190703.txt.gz).

599 To identify cell-specific chromatin regions within the epigenome map of human blood lineages<sup>27</sup>, we conducted differential analysis on sequencing data sourced from the 600 601 Gene Expression Omnibus (GEO) under accession GSE74912. To ensure a consistent 602 evaluation of the generated LD-sc statistics, which rely on the overall genomic coverage 603 of the tested chromatin regions, we selected an identical number of the most specific open chromatin regions from each blood lineage for subsequent heritability analysis by 604 LDSC. For contextual comparison of heritability signal with the other diseases, we 605 acquired summary statistics of Crohn's disease<sup>80</sup>, rheumatoid arthritis<sup>81</sup>, systemic lupus 606 erythematosus<sup>82</sup>, multiple sclerosis<sup>83</sup>, or Alzheimer's disease<sup>84</sup>. Similarly to the FUMA 607

analysis, the MHC region was excluded but otherwise the default parameters of LDSCwere used for the analysis.

610 eQTL analysis using published datasets

We interrogated a previously published dataset<sup>28</sup> for SNPs associated with mLOY in our European ancestry cohort. Chromosome, position, and alleles were used as unique identifiers with which to cross-reference SNPs across different immune cell subsets.

## 615 Transcriptomic imputation model construction and transcriptome-wide association study

616 Transcriptomic imputation models were constructed as previously described<sup>85,86</sup> for tissues of the GTEx<sup>87</sup> v8, STARNET<sup>29</sup> and PsychENCODE<sup>30,88</sup> cohorts. For GTEx 617 and STARNET cohorts, we considered adipose tissue: subcutaneous (GTEx & 618 619 STARNET) and visceral (GTEx & STARNET); arterial tissue: aorta (GTEx & STARNET), coronary (GTEx), mammary (STARNET), and tibial (GTEx); blood (GTEx & 620 621 STARNET); cell lines (GTEx): EBV-transformed lymphocytes and transformed fibroblasts; endocrine (GTEx): adrenal gland, pituitary, and thyroid; colon (GTEx): 622 sigmoid and trasverse; esophagus (GTEx): gastroesophageal junction, mucosa and 623 624 mascularis; pancreas (GTEx); salivary gland minor (GTEx); stomach (GTEx); terminal 625 ileum (GTEx); heart (GTEx): atrial appendage and left ventricle; liver (GTEx & STARNET), skeletal muscle (GTEx & STARNET); nerve tibial (GTEx); reproductive 626 627 (GTEx): mammary tissue, ovary, prostate, testis, uterus, vagina; lung (GTEx); skin (GTEx): not sun exposed suprapubic and sun exposed lower leg; and spleen (GTEx). 628 From PsychENCODE<sup>30,88</sup> we considered brain: dorsolateral prefrontal cortex (DLPFC) 629 genes. The genetic datasets of the GTEx<sup>87</sup>, STARNET<sup>29</sup> and PsychENCODE<sup>88</sup> cohorts 630

631 were uniformly processed for quality control (QC) steps before genotype imputation as previously described<sup>85,86</sup>. We restricted our analysis to samples with European ancestry 632 as previously described<sup>85</sup>. Genotypes were imputed using the University of Michigan 633 server<sup>89</sup> with the Haplotype Reference Consortium (HRC) reference panel<sup>90</sup>. Gene 634 635 expression information was derived from RNA-seg gene level counts, which were 636 adjusted for known and hidden confounders, followed by quantile normalization. For 637 GTEx, we used publicly available, quality-controlled, gene expression datasets from the GTEx consortium (http://www.gtexportal.org/). RNA-seg data for STARNET were 638 obtained in the form of residualized gene counts from a previously published study<sup>29</sup>. 639 For the dorsolateral prefrontal cortex from PsychENCODE we used post-quality-control 640 641 RNA-seq data that were fully processed, filtered, normalized, and extensively corrected for all known biological and technical covariates except the diagnosis status<sup>30</sup> as 642 previously described<sup>86</sup>. Feature types queried include genes, long non-coding RNA 643 (lincRNA), microRNA, processed transcripts, pseudogenes, RNA, small nucleolar RNA 644 645 (snoRNA), plus constant (C), joining (J), and variable (V) gene segments.

646 For population classification we used individuals of known ancestry from 1000 647 Genomes. We excluded variants in regions of high linkage disequilibrium, variants with 648 MAF<0.05, variant with high missingness (>0.01), and variants with Hardy-Weinberg equilibrium  $P < 1 \times 10^{-10}$ ; the remaining variants were pruned (--indep-pairwise 1000 10 649 0.02 with PLINK<sup>91</sup>) and PCA was performed with PLINK<sup>77</sup> version 2.0. We used the first 650 (PC1), second (PC2) and third (PC3) ancestral PCs to define an ellipsoid based on 651 1000Gp3v5 EUR samples<sup>59</sup> and samples within 3 SD from the ellipsoid center were 652 653 classified as EUR; based on this definition of EUR samples, we excluded one non-

654 European ancestry individual. In the remaining samples (n = 405), we performed 655 additional sample-level quality control by retaining non-related samples (--king-cutoff 0.0884 with PLINK<sup>77</sup> version 2.0) with sample-level missingness < 0.015 for variants 656 657 with variant-level missingness < 0.02, and heterozygosity rate of < 3SD away from the mean; of note, no samples were excluded by these steps. For the next step of our 658 659 pipeline, we performed outlier testing in the gene expression data. After performing 660 counts per million filtering (> 0.5 counts per million in at least 30% of samples) and 661 voom normalization, PCA was performed, and we excluded individuals located more than 4 SD away from the mean of the ellipsoid defined by PC1 to PC3. This did not 662 663 remove any individuals but assured us that our data did not contain any outliers. In this 664 final set of individuals, we performed variant-level quality control of the genotypes by 665 removing variants with less than 0.01 minor allele frequency (for all variants possible, 666 we utilized minor allele frequencies reported by Allele Frequency Aggregator European population<sup>92</sup>, to reduce minor allele frequency bias from the comparatively small 667 668 imputation model training population), 5 minor allele counts and 0.02 missingness rate; 669 only variants present in the reference panel of the Haplotype Reference Consortium were retained to ensure good representation of variants in the target GWAS<sup>90</sup>. We used 670 671 this final set of quality-controlled genotypes in conjunction with our normalized 672 expression data to discover the optimal number of PEER factors to find expression quantitative trait loci. Our analysis led to the decision to utilize 15 PEER factors, which 673 had resulted in the discovery of 4,299 significant eQTLs<sup>93</sup>. This was the closest value to 674 675 90% of the maximum value of eQTLs discovered by any chosen number of PEER 676 factors (4,844 significant eQTLs from 50 PEER factors). This allowed us to retain the

maximum signal for gene expression prediction without overcorrecting our data. After residualization for 15 PEER factors, expression data were quantile normalized. Genotypes were then converted to dosages, and missing values were replaced with twice the variant's minor allele frequency before dosages were rounded to the nearest whole number. For training, we used PrediXcan<sup>94</sup> for the construction of the retinal transcriptomic imputation model due to a lack of SNP epigenetic annotation information; for all other models, we used EpiXcan<sup>85</sup>.

## 684 *Multi-tissue transcriptome-wide association study (TWAS)*

We performed a gene-trait association analysis as previously described<sup>85</sup>. We applied the S-PrediXcan method<sup>95</sup> to integrate the summary statistics and the transcriptomic imputation models constructed above to obtain gene-level association results. *P*-values were adjusted for multiple testing using the Benjamini & Hochberg (FDR) method and Bonferroni correction. *P*-values across tissues were meta-analyzed using ACAT<sup>31</sup> ≤0.05 and predictive r<sup>2</sup>>0.01 to control for both significance and variance explained.

## 692 Summary-data-based Mendelian randomization

To test for joint associations between GWAS summary statistics SNPs and eQTL, the SMR method<sup>96</sup>, a Mendelian randomization approach, was used. Top SNPs used in SMR for each probe were selected as the most significant SNP in the eQTL data which was also present in the GWAS data. The SMR software (v1.03) was run using the default settings using GTEx Consortium<sup>87</sup> v8 whole blood tissue. European samples of the 1KGP were used as a reference panel. Bonferroni multiple-testing

699 correction was applied on SMR P-values (PSMR). Moreover, a post-filtering step was 700 applied by conducting heterogeneity in dependent instruments (HEIDI) test. The HEIDI 701 test distinguishes the causality and pleiotropy models from the linkage model by 702 considering the pattern of associations using all the SNPs that are significantly 703 associated with gene expression in the cis-eQTL region. The null hypothesis is that a 704 single variant is associated with both trait and gene expression, while the alternative 705 hypothesis ( $P_{HFIDI} < 0.05$ ) is that trait and gene expression are associated with two 706 distinct variants. The same tissues as in the TWAS section from the V8 release of the GTEx Consortium<sup>87</sup> were queried in SMR. 707

## 708 Heritability and genetic correlation analyses

Genetic correlation analyses were performed using linkage disequilibrium score regression (LDSC)<sup>97</sup> using the provided European-ancestry LD scores derived from 1KGP, as implemented in LDHub (v1.9.0)<sup>98</sup>. Bonferroni multiple testing correction was applied. SNPs from the MHC region (chr6:26M~34M) were removed.

## 713 Association of PGS Catalog-based polygenic scores with mLOY status

Phenome-wide polygenic score files for 2,652 traits were obtained from European Molecular Biology Laboratory's European Bioinformatics Institute (EMBL-EBI) PGS Catalog (September 2022 version)<sup>32</sup>. All EUR-ancestry subjects in MVP were scored across all available PGSs, excluding those derived from other MVP studies (20), using the +score plugin (<u>https://github.com/freeseek/score</u>) of bcftools<sup>65</sup>. PGSs were loaded into the dosage format field of VCFs readable by SAIGE v1.1.6.2<sup>99</sup> for association testing. Logistic regression was used to examine associations of PGSs on

MVP EUR mLOY cases and controls, adjusting for the same covariates as in GWAS (sex, age, mean-centered age-squared, and 20 ancestry-specific PCs).

## 723 Conditional meta-analysis (mtCOJO)

In order to assess the residual effects of genetic predisposition to cigarette smoking from mLOY susceptibility, we conducted a multi-trait meta-analysis<sup>25</sup> conditioned on cigarettes per day<sup>34</sup>. The conditional meta-analyses were performed using the EUR mLOY summary statistics using GCTA-mtCOJO<sup>46</sup>. The EUR LD panel described above for use with COJO was also used in this analysis.

## 729 Polygenic risk scoring

UKB summary statistics<sup>1</sup> were used to construct a polygenic risk score for EUR MVP participants with PRS-CS<sup>100</sup> (v20210604) with a global shrinkage prior of  $1 \times 10^{-4}$ . European samples of the 1KGP were used as a reference panel. Variants were filtered to include only those with R<sup>2</sup>>0.8 and MAF>1%.

## 734 Univariable and multivariable Mendelian randomization

735 Forward and reverse two-sample Mendelian randomization was performed using 736 summary statistics from previous European GWAS. Summary statistics were accessed through the OpenGWAS database API<sup>101</sup> via the GWAS codes listed in **Supplementary** 737 738 Data 20-22, except body mass index in males only from the GIANT (Genetic Investigation of ANthropometric Traits) consortium<sup>102</sup>, and cigarettes per day from the 739 GSCAN (GWAS & Sequencing Consortium of Alcohol and Nicotine use) consortium<sup>38</sup>. 740 741 which were downloaded separately. The genome-wide significance threshold of  $P < 5 \times 10^{-8}$  was used for the selection of genetic instrumental variables. LD clumping of 742

 $r^2$ <0.001 within a 10 Mb window was used to identify independent instruments. 743 744 Selection, clumping, and harmonization of instruments was performed using TwoSampleMR (v0.5.7)<sup>103</sup>. Primary analyses used the random-effect inverse-variance 745 746 weighted (IVW) method. Sensitivity analyses were performed with the MendelianRandomization (v0.6.0) R package<sup>104</sup> using fixed effect IVW, and by 747 748 achieving a nominal significance threshold (P<0.05) using one of either MR-Egger, 749 weighted median or weighted mode methods. Additionally we required P>0.05 for MR-Egger intercept. MR-PRESSO was conducted using MRPRESSO (v1.0) to test for 750 horizontal pleiotropy<sup>105</sup>. 751

752 To control for the possibility that genetic instruments related to mLOY displayed possible horizontal pleiotropic effects via smoking behavior, we conducted multivariable 753 Mendelian randomization (MVMR) using the MVMR R package v0.4<sup>106</sup> and included a 754 second exposure of cigarettes per day<sup>38</sup>. We report inverse-variance weighted 755 756 multivariable MR results along with the test for heterogeneity from a modified form of 757 Cochran's Q statistic with respect to differences in MVMR estimates across the set of 758 instruments. Covariance between the effect of genetic variants derived from the two exposures was fixed to zero due to the use of non-overlapping samples. The F-statistic 759 760 for instrument strength achieved *F*>10 for all tests.

761

## 762 **\*Consortium authors and affiliations**

## 763 VA Million Veteran Program

J. Michael Gaziano<sup>33,34</sup>, Philip S. Tsao<sup>16,17,18</sup>, Saiju Pyarajan<sup>1,32</sup>

765 <sup>33</sup>Massachusetts Veterans Epidemiology Research and Information Center (MAVERIC), VA

- 766 Boston Healthcare System, Boston, MA, USA; <sup>34</sup>Division of Aging, Department of Medicine,
- 767 Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA
- 768

# 769 Data availability

The full summary level association data from the meta-analysis and individual population association analyses in MVP will be available via the dbGaP study accession number phs001672. Full transcriptome-wide association study results are available upon request.

- 774
- 775

## 776 Competing interests

777 A.G.B. is on the scientific advisory board of TenSixteen Bio unrelated to the present 778 work. P.N. reports research grants from Allelica, Amgen, Apple, Boston Scientific, 779 Genentech / Roche, and Novartis, personal fees from Allelica, Apple, AstraZeneca, 780 Blackstone Life Sciences, Creative Education Concepts, CRISPR Therapeutics, Eli Lilly 781 & Co, Foresite Labs, Genentech / Roche, GV, HeartFlow, Magnet Biomedicine, Merck, 782 and Novartis, scientific advisory board membership of Esperion Therapeutics, Preciseli, and TenSixteen Bio, scientific co-founder of TenSixteen Bio, equity in MyOme, 783 784 Preciseli, and TenSixteen Bio, and spousal employment at Vertex Pharmaceuticals, all unrelated to the present work. D.K. is a scientific advisor and reports consulting fees 785 from Bitterroot Bio, Inc unrelated to the present work. The other authors declare no 786 787 competing interests.

# 788 References

- 1. Thompson, D. J. et al. Genetic predisposition to mosaic Y chromosome loss in blood.
- 790 *Nature* **575**, 652–657 (2019).
- 2. Forsberg, L. A. et al. Mosaic loss of chromosome Y in leukocytes matters. Nature genetics
- 792 vol. 51 4–7 (2019).
- Zekavat, S. M. *et al.* Hematopoietic mosaic chromosomal alterations increase the risk for
  diverse types of infection. *Nat. Med.* 27, 1012–1024 (2021).
- 4. Loh, P.-R., Genovese, G. & McCarroll, S. A. Monogenic and polygenic inheritance become
  instruments for clonal selection. *Nature* 584, 136–141 (2020).
- 797 5. Quintana-Murci, L. & Fellous, M. The Human Y Chromosome: The Biological Role of a
  798 'Functional Wasteland'. *J Biomed Biotechnol.* 1, 18–24 (2001).
- Pierre, R. V. & Hoagland, H. C. Age-associated aneuploidy: loss of Y chromosome from
  human bone marrow cells with aging. *Cancer* 30, 889–894 (1972).
- 7. Hubbard, A. K., Brown, D. W. & Machiela, M. J. Clonal hematopoiesis due to mosaic
- 802 chromosomal alterations: Impact on disease risk and mortality. *Leuk. Res.* 126, 107022
  803 (2023).
- 804 8. Dumanski, J. P. *et al.* Immune cells lacking Y chromosome show dysregulation of
  805 autosomal gene expression. *Cell. Mol. Life Sci.* **78**, 4019–4033 (2021).
- 806 9. Kar, S. P. *et al.* Genome-wide analyses of 200,453 individuals yield new insights into the
  807 causes and consequences of clonal hematopoiesis. *Nat. Genet.* 54, 1155–1166 (2022).
- 808 10. Kessler, M. D. *et al.* Common and rare variant associations with clonal haematopoiesis
  809 phenotypes. *Nature* 612, 301–309 (2022).
- 11. Jakubek, Y. A., Reiner, A. P. & Honigberg, M. C. Risk factors for clonal hematopoiesis of
  indeterminate potential and mosaic chromosomal alterations. *Transl. Res.* 255, 171–180
- 812 (2023).

- 813 12. Ljungström, V. et al. Loss of Y and clonal hematopoiesis in blood-two sides of the same
- 814 coin? *Leukemia* **36**, 889–891 (2021).
- 13. Jaiswal, S. *et al.* Clonal Hematopoiesis and Risk of Atherosclerotic Cardiovascular Disease.
- 816 *N. Engl. J. Med.* **377**, 111–121 (2017).
- 817 14. Sano, S. et al. Hematopoietic loss of Y chromosome leads to cardiac fibrosis and heart
- 818 failure mortality. *Science* **377**, 292–297 (2022).
- 819 15. Abdel-Hafiz, H. A. *et al.* Y chromosome loss in cancer drives growth by evasion of adaptive
  820 immunity. *Nature* 619, 624–631 (2023).
- 16. Pan-UKB team. https://pan.ukbb.broadinstitute.org. (2020).
- 17. Wright, D. J. et al. Genetic variants associated with mosaic Y chromosome loss highlight
- cell cycle genes and overlap with cancer susceptibility. *Nat. Genet.* **49**, 674–679 (2017).
- 18. Zhou, W. *et al.* Mosaic loss of chromosome Y is associated with common variation near
- 825 TCL1A. Nat. Genet. 48, 563–568 (2016).
- 19. Terao, C. *et al.* GWAS of mosaic loss of chromosome Y highlights genetic effects on blood
  cell differentiation. *Nat. Commun.* **10**, 4719 (2019).
- 828 20. Gaziano, J. M. *et al.* Million Veteran Program: A mega-biobank to study genetic influences
  829 on health and disease. *J. Clin. Epidemiol.* **70**, 214–223 (2016).
- 830 21. Hunter-Zinck, H. *et al.* Genotyping Array Design and Data Quality Control in the Million
  831 Veteran Program. *Am. J. Hum. Genet.* **106**, 535–548 (2020).
- 832 22. Scheller, M. et al. Hotspot DNMT3A mutations in clonal hematopoiesis and acute myeloid
- leukemia sensitize cells to azacytidine via viral mimicry response. *Nat Cancer* 2, 527–544
  (2021).
- 835 23. Cerchione, C. *et al.* IDH1/IDH2 Inhibition in Acute Myeloid Leukemia. *Front. Oncol.* 11,
  836 639387 (2021).
- 837 24. Han, B. & Eskin, E. Random-effects model aimed at discovering associations in meta-
- analysis of genome-wide association studies. *Am. J. Hum. Genet.* **88**, 586–598 (2011).

839 25. Atkinson, E. G. <i>et al.</i> Tracto	r uses local ancestr	y to enable the inclusion of	of admixed
--	----------------------	------------------------------	------------

- 840 individuals in GWAS and to boost power. *Nat. Genet.* **53**, 195–204 (2021).
- 26. Meuleman, W. *et al.* Index and biological spectrum of human DNase I hypersensitive sites.
- 842 *Nature* **584**, 244–251 (2020).
- 843 27. Corces, M. R. *et al.* Lineage-specific and single-cell chromatin accessibility charts human
- hematopoiesis and leukemia evolution. *Nat. Genet.* **48**, 1193–1203 (2016).
- 28. Yazar, S. *et al.* Single-cell eQTL mapping identifies cell type–specific genetic control of
  autoimmune disease. *Science* **376**, eabf3041 (2022).
- 29. Franzén, O. et al. Cardiometabolic risk loci share downstream cis- and trans-gene
- regulation across tissues and diseases. *Science* **353**, 827–830 (2016).
- 30. Gandal, M. J. *et al.* Transcriptome-wide isoform-level dysregulation in ASD, schizophrenia,
  and bipolar disorder. *Science* 362, (2018).
- 31. Liu, Y. et al. ACAT: A Fast and Powerful p Value Combination Method for Rare-Variant
- Analysis in Sequencing Studies. *Am. J. Hum. Genet.* **104**, 410–421 (2019).
- 32. Lambert, S. A. *et al.* The Polygenic Score Catalog as an open database for reproducibility
- and systematic evaluation. *Nat. Genet.* **53**, 420–425 (2021).
- 33. Zhu, Z. *et al.* Causal associations between risk factors and common diseases inferred from
  GWAS summary data. *Nat. Commun.* 9, 1–12 (2018).
- 857 34. Liu, M. *et al.* Association studies of up to 1.2 million individuals yield new insights into the
  858 genetic etiology of tobacco and alcohol use. *Nat. Genet.* **51**, 237–244 (2019).
- 35. Icick, R. et al. Genetic susceptibility to nicotine addiction: Advances and shortcomings in
- 860 our understanding of the CHRNA5/A3/B4 gene cluster contribution. *Neuropharmacology*
- **177**, 108234 (2020).
- 36. Loftfield, E. *et al.* Mosaic Y Loss Is Moderately Associated with Solid Tumor Risk. *Cancer Res.* **79**, 461–466 (2019).
- 37. Loftfield, E. et al. Predictors of mosaic chromosome Y loss and associations with mortality

- 865 in the UK Biobank. *Sci. Rep.* **8**, 12316 (2018).
- 38. Saunders, G. R. B. *et al.* Genetic diversity fuels gene discovery for tobacco and alcohol
- 867 use. *Nature* **612**, 720–724 (2022).
- 39. Kobayashi, T., Hachiya, T., Ikehata, Y. & Horie, S. Genetic association of mosaic loss of
- 869 chromosome Y with prostate cancer in men of European and East Asian ancestries: a
- 870 Mendelian randomization study. *Front Aging* **4**, 1176451 (2023).
- 40. Loh, P.-R. *et al.* Insights into clonal haematopoiesis from 8,342 mosaic chromosomal
  alterations. *Nature* 559, 350–355 (2018).
- 41. Taylor, W. R. & Stark, G. R. Regulation of the G2/M transition by p53. *Oncogene* 20, 1803–
  1815 (2001).
- 42. Porta, C., Paglino, C. & Mosca, A. Targeting PI3K/Akt/mTOR Signaling in Cancer. *Front. Oncol.* 4, 64 (2014).
- 43. Lin, S.-H. *et al.* Mosaic chromosome Y loss is associated with alterations in blood cell
  counts in UK Biobank men. *Sci. Rep.* **10**, 3655 (2020).
- 44. Hsu, J. I. *et al.* PPM1D Mutations Drive Clonal Hematopoiesis in Response to Cytotoxic
  Chemotherapy. *Cell Stem Cell* 23, 700–713.e6 (2018).
- 45. Wong, J. Y. Y. *et al.* Outdoor air pollution and mosaic loss of chromosome Y in older men
  from the Cardiovascular Health Study. *Environ. Int.* **116**, 239–247 (2018).
- 46. Dawoud, A. A. Z., Tapper, W. J. & Cross, N. C. P. Age-related loss of chromosome Y is
- associated with levels of sex hormone binding globulin and clonal hematopoiesis defined by
- 885 TET2, TP53, and CBL mutations. *Sci Adv* **9**, eade9746 (2023).
- 47. Markozannes, G. *et al.* Systematic review of Mendelian randomization studies on risk of
  cancer. *BMC Med.* 20, 1–22 (2022).
- 48. Nowak, C. & Ärnlöv, J. A Mendelian randomization study of the effects of blood lipids on
  breast cancer risk. *Nat. Commun.* 9, 3957 (2018).
- 49. Johnson, K. E. et al. The relationship between circulating lipids and breast cancer risk: A

891 Mendelian randomization study. *PLoS Med.* **17**, e1003302 (2020).

- 50. Orho-Melander, M. et al. Blood lipid genetic scores, the HMGCR gene and cancer risk: a
- 893 Mendelian randomization study. *Int. J. Epidemiol.* **47**, 495–505 (2018).
- 51. Hu, Y. et al. Minority-centric meta-analyses of blood lipid levels identify novel loci in the
- Population Architecture using Genomics and Epidemiology (PAGE) study. *PLoS Genet.* 16,
  e1008684 (2020).
- 52. Richardson, T. G. et al. Evaluating the relationship between circulating lipoprotein lipids and
- apolipoproteins with risk of coronary heart disease: A multivariable Mendelian
- randomisation analysis. *PLoS Med.* **17**, e1003062 (2020).
- 53. Owoicho, O. *et al.* Red blood cell distribution width as a prognostic biomarker for viral
- 901 infections: prospects and challenges. *Biomark. Med.* **16**, 41–50 (2022).
- 902 54. Faria, S. S. *et al.* The neutrophil-to-lymphocyte ratio: a narrative review.
- 903 Ecancermedicalscience **10**, 702 (2016).
- 904 55. Ethier, J.-L., Desautels, D., Templeton, A., Shah, P. S. & Amir, E. Prognostic role of
- 905 neutrophil-to-lymphocyte ratio in breast cancer: a systematic review and meta-analysis.
- 906 Breast Cancer Res. **19**, 2 (2017).
- 907 56. Danielsson, M. et al. Longitudinal changes in the frequency of mosaic chromosome Y loss
- 908 in peripheral blood cells of aging men varies profoundly between individuals. *Eur. J. Hum.*909 *Genet.* 28, 349–357 (2020).
- 910 57. Lee, W.-H. et al. Distinct genetic landscapes and their clinical implications in younger and
- 911 older patients with myelodysplastic syndromes. *Hematol. Oncol.* (2022)
- 912 doi:10.1002/hon.3109.
- 913 58. Teichman, R. Exposures of concern to veterans returning from Afghanistan and Iraq. *J.*
- 914 Occup. Environ. Med. 54, 677–681 (2012).
- 59. 1000 Genomes Project Consortium *et al.* A global reference for human genetic variation.
- 916 *Nature* **526**, 68–74 (2015).

- 917 60. Manichaikul, A. *et al.* Robust relationship inference in genome-wide association studies.
- 918 Bioinformatics **26**, 2867–2873 (2010).
- 919 61. Fang, H. *et al.* Harmonizing Genetic Ancestry and Self-identified Race/Ethnicity in Genome920 wide Association Studies. *Am. J. Hum. Genet.* **105**, 763–772 (2019).
- 921 62. Delaneau, O., Zagury, J.-F., Robinson, M. R., Marchini, J. L. & Dermitzakis, E. T. Accurate,
- scalable and integrative haplotype estimation. *Nat. Commun.* **10**, 5436 (2019).
- 923 63. Gurdasani, D. *et al.* The African Genome Variation Project shapes medical genetics in
  924 Africa. *Nature* **517**, 327–332 (2015).
- 925 64. Hinrichs, A. S. *et al.* The UCSC Genome Browser Database: update 2006. *Nucleic Acids*926 *Res.* 34, D590–8 (2006).
- 927 65. Danecek, P. et al. Twelve years of SAMtools and BCFtools. Gigascience 10, (2021).
- 928 66. Mbatchou, J., Barnard, L., Backman, J. & Marcketta, A. Computationally efficient whole
  929 genome regression for quantitative and binary traits. *bioRxiv* (2020).
- 930 67. Yang, J. et al. Conditional and joint multiple-SNP analysis of GWAS summary statistics
- 931 identifies additional variants influencing complex traits. *Nat. Genet.* 44, 369–75, S1–3
  932 (2012).
- 933 68. Wang, G., Sarkar, A., Carbonetto, P. & Stephens, M. A simple new approach to variable
- 934 selection in regression, with application to genetic fine mapping. *J. R. Stat. Soc. Series B*935 *Stat. Methodol.* 82, 1273–1300 (2020).
- 936 69. Benner, C. *et al.* FINEMAP: efficient variable selection using summary data from genome937 wide association studies. *Bioinformatics* 32, 1493–1501 (2016).
- 938 70. Mizrahi Man, O. et al. Novel genotyping algorithms for rare variants significantly improve
- 939 the accuracy of Applied Biosystems <sup>™</sup> Axiom <sup>™</sup> array genotyping calls. *bioRxiv* (2021)
- 940 doi:10.1101/2021.09.13.459984.
- 941 71. Cirulli, E. T. *et al.* Genome-wide rare variant analysis for thousands of phenotypes in over
- 942 70,000 exomes from two cohorts. *Nat. Commun.* **11**, 542 (2020).

- 943 72. Karczewski, K. J. *et al.* Author Correction: The mutational constraint spectrum quantified
  944 from variation in 141,456 humans. *Nature* **590**, E53 (2021).
- 945 73. Watanabe, K., Taskesen, E., van Bochoven, A. & Posthuma, D. Functional mapping and
- 946 annotation of genetic associations with FUMA. *Nat. Commun.* **8**, 1826 (2017).
- 947 74. Mao, X. *et al.* A genomewide admixture mapping panel for Hispanic/Latino populations.
- 948 Am. J. Hum. Genet. **80**, 1171–1178 (2007).
- 949 75. Martin, A. R. *et al.* Human Demographic History Impacts Genetic Risk Prediction across
  950 Diverse Populations. *Am. J. Hum. Genet.* **100**, 635–649 (2017).
- 951 76. Maples, B. K., Gravel, S., Kenny, E. E. & Bustamante, C. D. RFMix: a discriminative
- 952 modeling approach for rapid and robust local-ancestry inference. *Am. J. Hum. Genet.* **93**,
- 953 278–288 (2013).
- 954 77. Chang, C. C. *et al.* Second-generation PLINK: rising to the challenge of larger and richer
  955 datasets. *Gigascience* 4, 7 (2015).
- 956 78. Liberzon, A. *et al.* The molecular signatures database (MSigDB) hallmark gene set
  957 collection. Cell Syst. 2015; 1 (6): 417--25.
- 958 79. Finucane, H. K. *et al.* Partitioning heritability by functional annotation using genome-wide
  959 association summary statistics. *Nat. Genet.* 47, 1228–1235 (2015).
- 80. Liu, J. Z. *et al.* Association analyses identify 38 susceptibility loci for inflammatory bowel
  disease and highlight shared genetic risk across populations. *Nat. Genet.* 47, 979–986
  (2015).
- 963 81. Okada, Y. *et al.* Genetics of rheumatoid arthritis contributes to biology and drug discovery.
  964 *Nature* **506**, 376–381 (2014).
- 82. Bentham, J. *et al.* Genetic association analyses implicate aberrant regulation of innate and
- 966 adaptive immunity genes in the pathogenesis of systemic lupus erythematosus. *Nat. Genet.*
- **47**, 1457–1464 (2015).
- 968 83. International Multiple Sclerosis Genetics Consortium. Multiple sclerosis genomic map

- 969 implicates peripheral immune cells and microglia in susceptibility. *Science* **365**, (2019).
- 970 84. Kunkle, B. W. et al. Genetic meta-analysis of diagnosed Alzheimer's disease identifies new
- 971 risk loci and implicates Aβ, tau, immunity and lipid processing. *Nat. Genet.* **51**, 414–430
- 972 (2019).
- 973 85. Zhang, W. *et al.* Integrative transcriptome imputation reveals tissue-specific and shared
- 974 biological mechanisms mediating susceptibility to complex traits. *Nat. Commun.* **10**, 3834
- 975 (2019).
- 86. Fullard, J. F. *et al.* Single-nucleus transcriptome analysis of human brain immune response
- 977 in patients with severe COVID-19. *Genome Med.* **13**, 118 (2021).
- 978 87. GTEx Consortium. The GTEx Consortium atlas of genetic regulatory effects across human
  979 tissues. *Science* 369, 1318–1330 (2020).
- 88. Wang, D. *et al.* Comprehensive functional genomic resource and integrative model for the
  human brain. *Science* 362, (2018).
- 982 89. Das, S. *et al.* Next-generation genotype imputation service and methods. *Nat. Genet.* 48,
  983 1284–1287 (2016).
- 984 90. McCarthy, S. *et al.* A reference panel of 64,976 haplotypes for genotype imputation. *Nat.*985 *Genet.* 48, 1279–1283 (2016).
- 986 91. Purcell, S. *et al.* PLINK: a tool set for whole-genome association and population-based
  987 linkage analyses. *Am. J. Hum. Genet.* **81**, 559–575 (2007).
- 988 92. Phan, L. *et al.* ALFA: allele frequency aggregator. *National Center for Biotechnology*989 *Information, US National Library of Medicine* (2020).
- 93. Ongen, H., Buil, A., Brown, A. A., Dermitzakis, E. T. & Delaneau, O. Fast and efficient QTL
  mapper for thousands of molecular phenotypes. *Bioinformatics* 32, 1479–1485 (2016).
- 992 94. Gamazon, E. R. *et al.* A gene-based association method for mapping traits using reference
  993 transcriptome data. *Nat. Genet.* 47, 1091–1098 (2015).
- 994 95. Barbeira, A. N. et al. Exploring the phenotypic consequences of tissue specific gene

995 expression variation inferred from GWAS summary statistics. *Nat. Commun.* **9**, 1825

996 (2018).

- 997 96. Zhu, Z. et al. Integration of summary data from GWAS and eQTL studies predicts complex
- 998 trait gene targets. *Nat. Genet.* **48**, 481–487 (2016).
- 999 97. Bulik-Sullivan, B. K. *et al.* LD Score regression distinguishes confounding from polygenicity
- 1000 in genome-wide association studies. *Nat. Genet.* **47**, 291–295 (2015).
- 1001 98. Zheng, J. et al. LD Hub: a centralized database and web interface to perform LD score
- 1002 regression that maximizes the potential of summary level GWAS data for SNP heritability
- and genetic correlation analysis. *Bioinformatics* **33**, 272–279 (2017).
- 1004 99. Zhou, W. *et al.* Efficiently controlling for case-control imbalance and sample relatedness in

1005 large-scale genetic association studies. *Nat. Genet.* **50**, 1335–1341 (2018).

- 1006 100.Ge, T., Chen, C.-Y., Ni, Y., Feng, Y.-C. A. & Smoller, J. W. Polygenic prediction via
- 1007 Bayesian regression and continuous shrinkage priors. *Nat. Commun.* **10**, 1–10 (2019).

1008 101.Elsworth, B. et al. The MRC IEU OpenGWAS data infrastructure. bioRxiv

1009 2020.08.10.244293 (2020) doi:10.1101/2020.08.10.244293.

- 1010 102. Pulit, S. L. et al. Meta-analysis of genome-wide association studies for body fat distribution
- 1011 in 694,649 individuals of European ancestry. Preprint at https://doi.org/10.1101/304030.
- 1012 103. Hemani, G. *et al.* The MR-Base platform supports systematic causal inference across the
  1013 human phenome. *Elife* 7, e34408 (2018).
- 1014 104.Broadbent, J. R. *et al.* MendelianRandomization v0.5.0: updates to an R package for
- performing Mendelian randomization analyses using summarized data. *Wellcome Open Research* 5, (2020).
- 1017 105. Verbanck, M., Chen, C.-Y., Neale, B. & Do, R. Detection of widespread horizontal
- 1018 pleiotropy in causal relationships inferred from Mendelian randomization between complex

1019 traits and diseases. *Nat. Genet.* **50**, 693–698 (2018).

1020 106. Sanderson, E., Spiller, W. & Bowden, J. Testing and correcting for weak and pleiotropic

- 1021 instruments in two-sample multivariable Mendelian randomization. Stat. Med. 40, 5434–
- 1022 5452 (2021).



**Fig. 1. Mosaic loss of Y chromosome (mLOY) in the Million Veteran Program (MVP). a**, Median genotyping probe intensity log R ratio (LRR) vs. phased B Allele Frequency (BAF) in the pseudo-autosomal regions (PAR) 1 and 2. **b**, Density of age distribution in all MVP mLOY cases and controls. **c**, Percentage of individuals with mLOY per ten-year age bin for MVP European (EUR), African (AFR), and Hispanic (HIS) cohorts. Error bars represent 95% confidence intervals. **d**, Manhattan plot shows the -log10(*P*) for associations of genetic variants with mLOY in the multi-ancestry meta-analysis. Novel mLOY index variants and variants within  $\pm$  50 Kb are highlighted in red. The red line indicates the genome-wide significance threshold (*P*<5×10<sup>-8</sup>). The grey dotted line represents a transition from linear to log-scale on the y-axis.



**Fig. 2. Global- and local-ancestry-adjusted GWAS of mosaic loss of Y in admixed African (AFR) ancestry Million Veteran Program participants. a**, Miami plot showing conventional AFR GWAS (top) and AFR vs. European (EUR) haplotype dosage enrichment (bottom). **b**, At 20q11 (*BCL2L1*) we observed inflation due to local ancestry. This inflation was resolved by separating the AFR and EUR tracts as shown in **c** and **d**.



**Fig. 3. Mosaic loss of Y by PRS decile and Mendelian randomization (MR). a**, Percentage of individuals with mLOY by PRS decile, stratified by age decile (plot grid) and BMI range (color). **b**, Forest plot showing exposure traits with significant results from random effects inverse-variance weighted (RE IVW) MR and corresponding multivariable MR (MVMR) with cigarettes per day as an additional exposure, on mLOY outcome in Million Veteran Program Europeans. **c**, Significant results from RE IVW MR and MVMR considering mLOY exposure on trait outcomes. CI, confidence interval.

1.05 Odds ratio ± 95% CI 1.06 (1.03, 1.09)

1.1

5.71×10<sup>-5</sup>

mLOY

Prostate cancer